New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
July 29, 2011
07:11 EDTMRK
theflyonthewall.com: Merck lowered top end of 2011 non-GAAP R&D expense target
Merck lowered the top end of its non-GAAP R&D expense target to a range of $8B-$8.3B for 2011. The company updated its anticipated consolidated non-GAAP 2011 tax rate to a range of 23%-24%. :theflyonthewall.com



News For MRK From The Last 14 Days
Check below for free stories on MRK the last two weeks.
There are 6 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 19, 2012
15:40 EDTMRK
theflyonthewall.com: Barron's top 1,000 financial advisors recommend buying dividend stocks
Barron's published their annual listing of the top 1,000 financial advisors. Their single biggest recommendation: blue-chip stocks that pay hefty dividend. Shares of General Electric (GE), with a dividend yield of 3.5%, Merck (MRK), paying 4.3%, or AT&T (T), at 5.9%to name a few, pay a higher yield than 10-year Treasury bonds.Reference Link :theflyonthewall.com

February 17, 2012
07:29 EDTMRK
theflyonthewall.com: Merck shares offer highly favorable risk/reward, says JPMorgan

Subscribe for More Information
:theflyonthewall.com

February 15, 2012
07:04 EDTMRK
theflyonthewall.com: Merck establishes joint venture with Supera Farma for Brazil commercialization
Merck, known as MSD outside the United States and Canada, announced the formation of a new joint venture with Supera Farma Laboratorios, a Brazilian pharmaceutical company co-owned by Cristalia and Eurofarma. The new JV will market, distribute and sell a portfolio of innovative pharmaceutical and branded generic products from Merck, Cristalia and Eurofarma solely in the Brazilian retail sector. :theflyonthewall.com

February 13, 2012
10:16 EDTMRK
theflyonthewall.com: Merck announces FDA approval of ZIOPTANTM

Subscribe for More Information
:theflyonthewall.com

February 10, 2012
16:09 EDTMRK
theflyonthewall.com: Watson Pharmaceuticals confirms Beyaz patent challenge
Watson Pharmaceuticals (WPI) confirmed that its subsidiary, Watson Laboratories, filed an Abbreviated New Drug Application with the U.S. Food and Drug FDA seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg. Watson's ANDA product is a generic version of Bayer HealthCare Pharmaceuticals' (BAYRY) Beyaz. Beyaz is an oral contraceptive indicated for use by women to prevent pregnancy, treat symptoms of premenstrual dysphoric disorder for women who choose to use an oral contraceptive for contraception, treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control, and raise folate levels in women who choose to use an oral contraceptive for contraception. :theflyonthewall.com
07:10 EDTMRK
theflyonthewall.com: FDA outlines plan for biotech drug copies, WSJ reports

Subscribe for More Information
:theflyonthewall.com